Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00951496 · ClinicalTrials.gov registry record · Phase 3
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 1,560
- Enrollment target
NCT00951496: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00951496 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 1,560 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00951496, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,560 participants
- Enrollment target
Study Summary
This randomized phase III trial studies bevacizumab and intravenous (given into a vein) chemotherapy to see how well they work compared with bevacizumab and intraperitoneal (given into the abdominal cavity) chemotherapy in treating patients with stage II-III ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Monoclonal antibodies, such as bevacizumab, can block the ability of tumor cells to grow and spread by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving bevacizumab together with intravenous chemotherapy is more effective than giving bevacizumab together with intraperitoneal chemotherapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,560 participants |
| Start Date | 2009-08-11 |
| Est. Completion | 2016-01-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00951496
The ClinicalTrials.gov registry entry for NCT00951496 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,560 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT00951496 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00951496 about?
NCT00951496 is a clinical study titled "Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer". This randomized phase III trial studies bevacizumab and intravenous (given into a vein) chemotherapy to see how well they work compared with bevacizumab and intraperitoneal (given into the abdominal cavity) chemotherapy in treating patients with stage II-III ovarian epithelial cancer, fallopian tube...
What is the current status of trial NCT00951496?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,560 participants. The study started on 2009-08-11. Estimated completion is 2016-01-11.
What interventions are being tested in trial NCT00951496?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Laboratory Biomarker Analysis (OTHER), Bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00951496?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.